In a unanimous panel opinion filed on February 18, 2025, the First Circuit held that False Claims Act cases predicated on violations of ...
Key Takeaways - The First Circuit ruled in United States v. Regeneron Pharmaceuticals, Inc., that the government must prove but-for causation ...
EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.
This was the stock's third consecutive day of gains.
Shannin Desroches fought for a diagnosis after being dismissed. Now she tells PEOPLE that she's been given a 5% chance of ...
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...
Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback